glp 1 that accepts medicaid More states consider dropping GLP-1 weight loss drugs from • Stateline Indiana Gov. Mike Braun is

Indian Heart J 70:S224S228

Previous drugs have been single- or dual-agonist drugs

current protocols have been refined through community experience

Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space

Furthermore, ACOG states not a single reputable study has succinctly concluded use of acetaminophen in any trimester of pregnancy results in neurodevelopmental disorders in the offspring and the two highest-quality studies on this subject did not find a significant association between use of acetaminophen during pregnancy and the risk of autism, ADHD or intellectual disability in the children